TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04379596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 5-FU: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion
Study: NCT03520595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium 50mg twice daily
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills and distilled water 3 pills,3 times daily
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Study: NCT00519701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Study: NCT02206217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiple-Segment spectacle lens
Description: A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
Study: NCT04285632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometrics exercises
Description: Counter Movement Jump exercise. The subject will be placed in an upright standing position, with his hands on his hip. It will perform a rapid downward movement in which it will flex the hips and knees and, immediately, a rapid extension of the legs that will result in the maximum vertical jump. During the flight phase the subject will keep the legs straight. The landing will be done with both feet at the same time. The intervention will be carried out for 300 seconds, in 2 series of 30 jumps each and with 3 minutes of rest between series.~Drop Jump exercise. The players will be placed on a step, standing and with their feet shoulder-width apart. They will drop forward, landing with both feet at the same time. Upon touching the ground they will perform a maximum vertical jump. The intervention will be carried out for 600 seconds, in 2 series of 25 jumps each, and with 3 minutes of rest between series.
Study: NCT04379596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: administered as an IV infusion
Study: NCT05197946

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Research unsedated MRI scans (outside of usual care) will be performed using a 3T Philips scanner at the F.M. Kirby Research Center. An MRI scanning protocol will be at the F.M. Kirby Research Center; the protocol will not last more than 1.5 hours. Acquisitions will include a triplanar survey, functional and anatomical multi-slice imaging of the brain as well as MRI of selected spinal levels. Protocols will be used that do not involve use of contrast agents and limit power/tissue absorption as well as otherwise remain within FDA and Kirby Center safety regulations. When possible, MRI will be performed within 3 months of initial survey/interview administration. If MRI is scheduled \>3 months after initial survey/interview administration, a brief survey will be re-administered to screen for changes in pain/clinical status.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Research unsedated MRI scans (outside of usual care) will be performed using a 3T Philips scanner at the F.M. Kirby Research Center. An MRI scanning protocol will be at the F.M. Kirby Research Center; the protocol will not last more than 1.5 hours. Acquisitions will include a triplanar survey, functional and anatomical multi-slice imaging of the brain as well as MRI of selected spinal levels. Protocols will be used that do not involve use of contrast agents and limit power/tissue absorption as well as otherwise remain within FDA and Kirby Center safety regulations. When possible, MRI will be performed within 3 months of initial survey/interview administration. If MRI is scheduled \>3 months after initial survey/interview administration, a brief survey will be re-administered to screen for changes in pain/clinical status.
Study: NCT03672110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: intervention: different advagraf dosing in the study compared to the control arm, see above

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: intervention: different advagraf dosing in the study compared to the control arm, see above
Study: NCT03177603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586881
Description: GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.
Study: NCT05014906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
Study: NCT04379596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin: administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion
Study: NCT00509236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 25 mg (one 25-mg tablet) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: 2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
Study: NCT04504201

Intervention type: OTHER
Intervention: Focus Group
Description: Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.

Intervention type: OTHER
Intervention: Focus Group
Description: Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
Study: NCT02504125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 100 mL of normal saline intravenously approximately 15 minutes before incision
Study: NCT04609202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse led person centred care
Description: Person centred care include patiens narratives, partnership and documentation of a health plan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided by doctors
Study: NCT04437095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Support Based on Positive Suggestion delivered via pre-recorded MP3 message
Description: Daily administration of audiorecording
Study: NCT04379596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Volrustomig: administered as an IV infusion
Study: NCT01770210

Intervention type: DRUG
Intervention: Patients on atorvastatin treatment
Description: Statins Therapy
Study: NCT04379596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Volrustomig: administered as an IV infusion
Study: NCT01209637

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: exercise training min. 4 times a day for at least 30 min

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive exercise training
Description: Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
Study: NCT02493400

Intervention type: OTHER
Intervention: No intervention in the follow up study.

Intervention type: OTHER
Intervention: No intervention in the follow up study.
Study: NCT04379596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig: administered as an IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig: administered as an IV infusion
Study: NCT04265430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Agent
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Agent
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05120518

Intervention type: OTHER
Intervention: Collection of post mortem tissue donation
Description: Collection of post mortem tissue from pediatric participants with cancer and non-cancer tumor types from whom post mortem tissue donation and autopsy consent is obtained.
Study: NCT04435756

Intervention type: OTHER
Intervention: Biomarker Analysis
Description: Correlative study

Intervention type: PROCEDURE
Intervention: Blood Product Collection
Description: Undergo collection of blood
Study: NCT02793674

Intervention type: DEVICE
Group type: OTHER
Intervention: Fisher & Paykel high flow nasal cannula
Description: Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Vapotherm high flow nasal cannula
Description: Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
Study: NCT00601172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant
Description: Experimental NK-1 receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Standard antiemetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Standard antiemetics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match IV casopitant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Standard antiemetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Standard antiemetics
Study: NCT02498353

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative short-course radiotherapy with local boost
Description: Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: preoperative short-course radiotherapy without local boost
Description: Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME surgery
Description: both study group and control group received surgery under TME principle after radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME surgery
Description: both study group and control group received surgery under TME principle after radiotherapy
Study: NCT04601558

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The letters with the Cochrane abstracts in the form of blog-shots
Description: The active intervention were letters with the remainder on participant's own cardiovascular risk factors, a participant's own count of 10-year risk of cardiovascular disease, and Cochrane abstract in the form of blog-shots and personal advice in reducing cardiovascular disease risk.~There were three Cochrane blog-shots. The first was about calcium in prevention of high blood pressure, the second was about the effect of reducing saturated fat acids in eating habits and the third consisted evidence of green and black tea for the prevention of cardiovascular diseases.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: The letters with remainder on cardiovascular risk factors
Description: The passive intervention were letters with the remainder on participant's own cardiovascular risk factors and participant's own count of 10-year risk of cardiovascular disease.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk.
Study: NCT03298282

Intervention type: OTHER
Intervention: OCT (Optical Coherence Tomography)
Description: Coronary images by OCT and selective CTA and FFR values will be registered.

Intervention type: OTHER
Intervention: Coronary CTA
Description: Coronary images by OCT and Coronary CTA and FFR values will be registered.

Intervention type: OTHER
Intervention: FFR
Description: Coronary images by OCT and selective CTA and FFR values will be registered.
Study: NCT03306901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 3,200 \~ 4,000mg/m2 intravenously for 4 to 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 45\~60mg intravenously over 1 hour on day 1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 45 Gy irradiation (5 days a week for 5 weeks)
Study: NCT03177603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586881
Description: GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586881
Description: GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586881
Description: GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.
Study: NCT03777670

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Drop of blood for RNA and metabolic analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Drop of blood for RNA and metabolic analysis
Study: NCT04543136

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeediCath® Standard male
Description: Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 1 catheter for males
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New intermittent Variant 2 catheter for males
Description: Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
Study: NCT00494104

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day
Description: Infants receive daily 0.5 ml of code labeled supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day
Description: Infants receive daily 0.5 ml of code labeled supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day
Description: Infants receive daily 0.5 ml of code labeled supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day
Description: Infants receive daily 0.5 ml of code labeled supplement
Study: NCT02470858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF+ASV
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV+SMV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+DCV+ASV
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
Study: NCT01432496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg
Description: Nebulization of Ropivacaine 150 mg in the peritoneal cavity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 15 ml
Description: Nebulization of saline 15 ml in the peritoneal cavity